Zacks Research Has Bullish Forecast for Clorox Q4 Earnings

The Clorox Company (NYSE:CLX) – Equities researchers at Zacks Research increased their Q4 2025 earnings per share estimates for shares of Clorox in a research note issued to investors on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $2.23 for the quarter, up from their prior estimate of $2.14. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $1.57 EPS, FY2026 earnings at $6.71 EPS, Q1 2027 earnings at $1.62 EPS, Q2 2027 earnings at $1.71 EPS and Q3 2027 earnings at $1.70 EPS.

Several other research firms also recently weighed in on CLX. Barclays cut their price objective on Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a report on Wednesday, May 7th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $150.00 price objective on shares of Clorox in a report on Thursday, January 30th. Evercore ISI set a $140.00 target price on shares of Clorox and gave the stock an “underperform” rating in a report on Tuesday, May 6th. Citigroup cut their price target on shares of Clorox from $165.00 to $150.00 and set a “neutral” rating on the stock in a report on Monday, April 14th. Finally, Wells Fargo & Company decreased their price objective on Clorox from $145.00 to $142.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $151.23.

Clorox Price Performance

CLX stock opened at $135.53 on Wednesday. The company has a 50 day simple moving average of $140.57 and a 200 day simple moving average of $152.97. The stock has a market cap of $16.70 billion, a price-to-earnings ratio of 37.03, a P/E/G ratio of 2.62 and a beta of 0.60. Clorox has a 1 year low of $127.60 and a 1 year high of $171.37. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60.

Clorox (NYSE:CLX) last released its quarterly earnings data on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.12). The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a net margin of 6.38% and a return on equity of 316.87%. The business’s quarterly revenue was down 8.0% compared to the same quarter last year. During the same period last year, the business earned $1.71 earnings per share.

Clorox Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, May 9th. Investors of record on Wednesday, April 23rd were paid a dividend of $1.22 per share. This represents a $4.88 dividend on an annualized basis and a yield of 3.60%. The ex-dividend date of this dividend was Wednesday, April 23rd. Clorox’s dividend payout ratio (DPR) is currently 87.61%.

Insiders Place Their Bets

In other news, Director Pierre R. Breber acquired 4,000 shares of the firm’s stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.57% of the company’s stock.

Institutional Investors Weigh In On Clorox

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Clorox by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company’s stock valued at $2,293,135,000 after purchasing an additional 65,924 shares during the last quarter. Geode Capital Management LLC lifted its stake in Clorox by 2.3% during the 4th quarter. Geode Capital Management LLC now owns 3,098,302 shares of the company’s stock valued at $501,925,000 after acquiring an additional 69,969 shares in the last quarter. Stifel Financial Corp lifted its stake in Clorox by 0.4% during the 4th quarter. Stifel Financial Corp now owns 2,344,408 shares of the company’s stock valued at $380,761,000 after acquiring an additional 9,582 shares in the last quarter. Norges Bank purchased a new position in Clorox during the 4th quarter worth $259,041,000. Finally, Northern Trust Corp grew its stake in shares of Clorox by 2.3% in the 1st quarter. Northern Trust Corp now owns 1,528,920 shares of the company’s stock worth $225,133,000 after acquiring an additional 34,655 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.